RNAC Stock Overview
A clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cartesian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.76 |
| 52 Week High | US$41.87 |
| 52 Week Low | US$11.67 |
| Beta | 0 |
| 1 Month Change | -0.37% |
| 3 Month Change | 9.64% |
| 1 Year Change | -9.29% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.56% |
Recent News & Updates
Cartesian Therapeutics: Uncertainty Remains
Nov 10Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Sep 17Shareholder Returns
| RNAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.0% | -1.7% | -1.1% |
| 1Y | -9.3% | -5.0% | 22.4% |
Return vs Industry: RNAC underperformed the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: RNAC underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| RNAC volatility | |
|---|---|
| RNAC Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RNAC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RNAC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 38 | Carsten Brunn | www.cartesiantherapeutics.com |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases.
Cartesian Therapeutics, Inc. Fundamentals Summary
| RNAC fundamental statistics | |
|---|---|
| Market cap | US$509.10m |
| Earnings (TTM) | -US$282.38m |
| Revenue (TTM) | US$47.94m |
10.1x
P/S Ratio-1.7x
P/E RatioIs RNAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNAC income statement (TTM) | |
|---|---|
| Revenue | US$47.94m |
| Cost of Revenue | US$49.83m |
| Gross Profit | -US$1.89m |
| Other Expenses | US$280.49m |
| Earnings | -US$282.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.98 |
| Gross Margin | -3.95% |
| Net Profit Margin | -589.05% |
| Debt/Equity Ratio | 0% |
How did RNAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 07:52 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cartesian Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| John Newman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |